DrugPatentWatch Database Preview
Investigational Drug Information for CAM2038
Email this page to a colleague
What is the development status for investigational drug CAM2038?
CAM2038 is an investigational drug.
There have been 10 clinical trials for CAM2038.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 21st 2020.
The most common disease conditions in clinical trials are Opioid-Related Disorders, Substance-Related Disorders, and Disease. The leading clinical trial sponsors are The Emmes Company, LLC, Braeburn Pharmaceuticals, and National Institute on Drug Abuse (NIDA).
There is one US patent protecting this investigational drug and nineteen international patents.
Summary for CAM2038
| US Patents | 1,379 |
| International Patents | 19,301 |
| US Patent Applications | 4,261 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 712 |
| Clinical Trial Progress | Phase 3 (2020-07-21) |
| Vendors | 10 |
Recent Clinical Trials for CAM2038
| Title | Sponsor | Phase |
|---|---|---|
| Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study | National Institute on Drug Abuse (NIDA) | Phase 3 |
| Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study | The Emmes Company, LLC | Phase 3 |
| Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study | The EMMES Corporation | Phase 3 |
Clinical Trial Summary for CAM2038
Top disease conditions for CAM2038
Top clinical trial sponsors for CAM2038
US Patents for CAM2038
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CAM2038 | ⤷ Sign up for a Free Trial | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | The Regents of the University of California (Oakland, CA) | ⤷ Sign up for a Free Trial |
| CAM2038 | ⤷ Sign up for a Free Trial | Methods and devices to reduce damaging effects of concussive or blast forces on a subject | TBI INNOVATIONS, LLC (Richmond, IN) THORNHILL RESEARCH, INC. (Toronto, Ontario, CA) | ⤷ Sign up for a Free Trial |
| CAM2038 | ⤷ Sign up for a Free Trial | Pharmaceutical formulations | GW Pharma Limited (Cambridge, GB) | ⤷ Sign up for a Free Trial |
| CAM2038 | ⤷ Sign up for a Free Trial | Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse | Acura Pharmaceuticals, Inc. (Palatine, IL) | ⤷ Sign up for a Free Trial |
| CAM2038 | ⤷ Sign up for a Free Trial | Tamper-resistant pharmaceutical compositions of opioids and other drugs | COLLEGIUM PHARMACEUTICAL, INC. (Canton, MA) | ⤷ Sign up for a Free Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CAM2038
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CAM2038 | European Patent Office | EP2981556 | 2033-04-02 | ⤷ Sign up for a Free Trial |
| CAM2038 | World Intellectual Property Organization (WIPO) | WO2014165513 | 2033-04-02 | ⤷ Sign up for a Free Trial |
| CAM2038 | Australia | AU2017260251 | 2036-05-03 | ⤷ Sign up for a Free Trial |
| CAM2038 | Canada | CA3022932 | 2036-05-03 | ⤷ Sign up for a Free Trial |
| CAM2038 | China | CN109414220 | 2036-05-03 | ⤷ Sign up for a Free Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
